key: cord-0330131-ugis461p
authors: Talaei, M.; Faustini, S.; Holt, H.; Jolliffe, D. A.; Vivaldi, G.; Greenig, M.; Perdek, N.; Maltby, S.; Symons, J.; Davies, G. A.; Lyons, R. A.; Griffiths, C. J.; Kee, F.; Sheikh, A.; Richter, A. G.; Shaheen, S. O.; Martineau, A. R.
title: Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)
date: 2021-11-03
journal: nan
DOI: 10.1101/2021.11.02.21265767
sha: e294e3a63da75b41bfc01898eb17b6b1b3373664
doc_id: 330131
cord_uid: ugis461p

Background: Prospective population-based studies investigating multiple determinants of pre-vaccination antibody responses to SARS-CoV-2 are lacking. Methods: We did a prospective population-based study in SARS-CoV-2 vaccine-naive UK adults between May 1 and Nov 2, 2020. Information on 88 potential risk factors was obtained through online questionnaires, and combined IgG/IgA/IgM responses to SARS-CoV-2 spike glycoprotein were determined in dried blood spots. We used logistic and linear regression to estimate adjusted odds ratios (aORs) and adjusted geometric mean ratios (aGMRs) for potential determinants of SARS-CoV-2 seropositivity (all participants) and antibody titres (seropositive participants only), respectively. Results: 1696 (15.2%) of 11,130 participants were seropositive. Factors independently associated with increased risk included frontline health/care occupation (aOR 1.86, 95% CI 1.49-2.33), international travel (1.22, 1.08-1.37), BMI >30 vs <25 kg/m2 (1.22, 1.05-1.42), Asian/Asian British vs White ethnicity (1.65, 1.10-2.47), and alcohol consumption [≥]15 vs 0 units/week (1.26, 1.06-1.49). Light physical exercise associated with decreased risk (0.80, 0.69-0.93, for [≥]10 vs 0-4 h/week). Higher titres associated with frontline health/care occupation (aGMR 1.26, 95% CI 1.13-1.41), international travel (1.10, 1.04-1.16), BMI >30 vs <25 kg/m2 (1.09, 1.01-1.17), and Asian/Asian British vs White ethnicity (1.23, 1.03-1.46); these associations were not substantially attenuated by adjustment for disease severity. Conclusions: Higher alcohol consumption and reduced physical exercise represent new modifiable risk factors for SARS-CoV-2 infection. Recognised associations between Asian/Asian British ethnic origin and obesity and increased risk of SARS-CoV-2 seropositivity were independent of other sociodemographic, clinical, or behavioural factors investigated.

The COVID-19 pandemic has caused more than 220 million recorded infections and over 4.5 million recorded deaths, 1 with these figures representing only a portion of the true burden. 2 Large, population-based studies have identified various risk factors for SARS-CoV-2 infection, including non-White ethnicity and lower educational attainment. [3] [4] [5] However, the vast majority of studies have been based on routine real-time reverse transcription PCR (RT-PCR) testing in healthcare settings or in the community; consequently, they are potentially open to collider bias, as the probability of being tested for infection can itself depend on the risk factors under investigation. 6 Access to testing has also changed across the course of the pandemic, 7 meaning earlier studies were more likely to focus on people with symptomatic disease or a history of travel, or on specific populations such as healthcare workers.

Serological population-based studies offer a different approach by testing members of a population uniformly, including people who might not be captured by routine testing. This approach not only reduces the risk of collider bias, but also can uncover previously undetected asymptomatic infections. Inclusion of asymptomatic SARS-CoV-2 infections in the analysis of risk factors is crucial, as asymptomatic individuals have been found to be as infectious as those with symptoms. 8 Serology studies also offer the opportunity to identify determinants of anti-SARS-CoV-2 antibody titres, which are a recognised correlate of protection against future infection. 9, 10 The largest population-based serology studies done to date have explored several sociodemographic and clinical risk factors, but have not considered risk factors related to lifestyle, diet, or levels of physical activity. [3] [4] [5] 11, 12 These studies have focused on IgG antibodies alone 11, 12 or relied on immunoassays with low sensitivity, 12 potentially missing infections. They have also tended to be cross-sectional in design, so that reverse causality could potentially explain associations between symptomatic seropositivity and modifiable risk factors. Additionally, studies investigating determinants of antibody titres have focused on specific populations such as healthcare workers, 13, 14 limiting the generalisability of their findings.

We therefore undertook a prospective population-based study to uncover determinants of SARS-CoV-2 seropositivity and antibody titres, combining high statistical power with detailed assessment of sociodemographic, clinical, and behavioural risk factors, and supported by an assay with proven sensitivity for detection of SARS-CoV-2 antibodies in non-hospitalised adults with mild or moderate COVID- 19. 15 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. ; https://doi.org/10.1101/2021.11.02.21265767 doi: medRxiv preprint

COVIDENCE UK is a prospective, longitudinal, population-based observational study of COVID-19 in the UK population (www.qmul.ac.uk/covidence). 16 Inclusion criteria were age 16 years or older and UK residence at enrolment, with no exclusion criteria. Participants were invited via a national media campaign to complete an online baseline questionnaire to capture: information on potential symptoms of COVID-19 experienced since Feb 1, 2020; results of any COVID-19 tests; and details of a wide range of potential risk factors for COVID-19 (appendix table S1). Online monthly follow-up questionnaires captured incident test-confirmed COVID- 19 and symptoms of acute respiratory infection (appendix table S2). The study was launched on May 1, 2020.

The antibody study described here was introduced as an approved protocol amendment (amendment 3; November, 2020). Participants enrolled before the amendment were invited via email to participate in the antibody study and to give additional consent. As part of the antibody study, participants were invited to participate in serology testing from November, 2020. For this analysis, we included all participants enrolled in the study by Nov 2, 2020, partaking in serology testing who were not vaccinated against COVID-19 or who provided their dried blood spot sample on or before the date of their first COVID-19 vaccination. This paper reports findings from analysis of data collected up to April 18, 2021 . 

Antibody study participants were sent a kit containing instructions, lancets, and blood spot collection cards, to be posted back to the study team. Once returned, the samples were logged by the study team and sent in batches to the Clinical Immunology Service at the Institute of Immunology and Immunotherapy of the University of Birmingham (Birmingham, UK). Up to two more test kits were offered to participants whose initial samples were found to be insufficient for testing. Samples were taken from Nov 6, 2020, to April 18, 2021.

Semi-quantitative determination of antibody titres was done using a commercially available ELISA that measures combined IgG, IgA, and IgM (IgGAM) responses to the SARS-CoV-2 trimeric spike glycoprotein (product code MK654; The Binding Site [TBS], Birmingham, UK).

The SARS-CoV-2 spike used is a soluble, stabilised, trimeric glycoprotein truncated at the transmembrane region. 17, 18 This assay has been CE-marked with 98.3% (95% CI 96. 4-99.4) specificity and 98.6% (92.6-100.0) sensitivity following RT-PCR-confirmed mild-to-moderate . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. ; https://doi.org/10.1101/2021.11.02.21265767 doi: medRxiv preprint COVID-19 that did not result in hospitalisation. 15 A cut-off ratio relative to the TBS cut-off calibrators was determined by plotting 624 pre-2019 negatives in a frequency histogram. A cut-off coefficient was then established for IgGAM (1.31), with ratio values classed as positive (≥1) or negative (<1). Dried blood spots were pre-diluted at a 1:40 dilution with 0.05% PBS-Tween using a Dynex Revelation automated absorbance microplate reader (Dynex Technologies; Chantilly, VA, USA). Plates were developed after 10 min using 3,3′,5,5′tetramethylbenzidine core, and orthophosphoric acid used as a stop solution (both TBS).

Optical densities at 450 nm were measured using the Dynex Revelation.

Study outcomes were presence versus absence of antibodies against SARS-CoV-2 (binary outcome assessed in all participants who did not report having tested positive for SARS-CoV-2 infection via RT-PCR or lateral flow test before enrolment), and antibody titres (continuous outcome considered in all seropositive participants).

88 putative risk factors for SARS-CoV-2 infection were selected a priori, covering sociodemographic, occupational, and lifestyle factors; longstanding medical conditions and prescribed medication use; Bacille Calmette Guérin and measles, mumps, and rubella vaccine status; and diet and supplemental micronutrient intake (appendix tables S1, S2). These factors, which were obtained from the baseline questionnaire, were included as independent variables in our models. To produce patient-level covariates for each class of medications investigated, participant responses were mapped to drug classes listed in the British National Formulary or the DrugBank and Electronic Medicines Compendium databases if not explicitly listed in the British National Formulary, as previously described. 16 Index of Multiple Deprivation (IMD) 2019 scores were assigned according to participants' postcodes, and categorised into quartiles.

The sample size required to obtain an odds ratio (OR) of at least 1.08 for a binary exposure with maximum variability (probability 0.50 changing to 0.52) and correlated with other variables in the model (R²=0.4), using a two-sided test with 90% power and 5% significance, was estimated as 10,964, using Stata's powerlog program. Assuming 10% censoring at baseline (i.e., participants with missing data or previous SARS-CoV-2 infection) and 20% loss to followup, we aimed to recruit a minimum of 15,228 participants into COVIDENCE UK, with no upper limit. The antibody study was a pragmatic study including all participants meeting the inclusion criteria, with no sample size specified. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. ; https://doi.org/10.1101/2021.11.02.21265767 doi: medRxiv preprint Logistic regression models were used to estimate ORs and 95% CIs for potential determinants of SARS-CoV-2 seropositivity. Linear regression models with robust standard errors were used to estimate geometric mean ratios (GMRs) and 95% CIs for potential determinants of log-transformed antibody titres in seropositive participants. We first estimated ORs and GMRs in minimally adjusted models, and included factors independently associated with each outcome at the 10% significance level in fully adjusted models. Both the minimally adjusted and fully adjusted models were controlled for age (<30 years, 30 to <40 years, 40 to <50 years, 50 to <60 years, 60 to <70 years, and ≥70 years), sex (male vs female), and duration of followup (days). We calculated p for trend for ordinal variables by re-running the regressions treating each ordinal variable in turn as continuous. Analyses were done for all participants with available data; missing data were not imputed. Correction for multiple comparisons was not applied, on the grounds that we were testing a priori hypotheses for all risk factors investigated. 19 In a sensitivity analysis, we excluded participants from the seropositivity analysis who were classified as having had probable COVID-19 before enrolment on the basis of self-reported symptoms, using the symptom algorithm described and validated by Menni and colleagues. 20 As antibody titres have been found to be associated with disease severity, 13, 21 we did an exploratory analysis to investigate the extent to which COVID-19 severity might explain associations between independent variables and antibody titres, by including this as an explanatory variable in the titre analysis. COVID-19 severity was classified into three groups:

'asymptomatic' (non-hospitalised seropositive participants, who either did not report any symptoms of acute respiratory infection or whose symptoms were classified as having <50% probability of being due to COVID-19, using the symptom algorithm by Menni and colleagues 20 ); 'symptomatic non-hospitalised' (non-hospitalised seropositive participants who reported symptoms of acute respiratory infection that were classified as having ≥50% probability of being due to COVID-19, using the symptom algorithm 20 ); and 'hospitalised' (seropositive participants who were hospitalised for treatment of COVID-19).

We present descriptive statistics as n (%), mean (SD), or median (IQR). Statistical analyses were done using Stata (version 14.2; StataCorp, College Station, TX, USA).

The study funders had no role in the study design, data analysis, data interpretation, or writing of the report. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. ; https://doi.org/10.1101/2021.11.02.21265767 doi: medRxiv preprint

Serology data were available for 12,294 of the 15,853 participants who consented to participate in the antibody study. We excluded data from 1074 participants who had been vaccinated against SARS-CoV-2 before providing their dried blood spot sample (figure 1). Of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. ; https://doi.org/10.1101/2021.11.02.21265767 doi: medRxiv preprint adjusted model, we found that Asian/Asian British ethnicity (vs White), having a mortgage (vs owning own home), working as a frontline worker in a health or care setting, being an exsmoker (vs a never-smoker), travel outside of the UK, taking multivitamin supplements, consuming at least two portions of dairy products or calcium-fortified alternatives (vs 0-1 portions), high BMI, and use of beta blockers were associated with higher antibody titres, whereas high levels of fruit, vegetable, or salad consumption and reporting feeling anxious or depressed at baseline were associated with lower antibody titres (table 3) . p-for-trend analyses suggested higher antibody titres with increasing intake of dairy or calcium-fortified alternatives and increasing BMI (table 3) . The associations in minimally adjusted models with chronic obstructive pulmonary disease, poor self-reported general health, and use of metformin or statins were attenuated in the fully adjusted model and were no longer statistically significant (table 3) .

The addition of COVID-19 severity to our model of determinants of antibody titres in seropositive participants attenuated the associations observed for BMI and smoking status, but significant associations remained for all other variables ( table 3 ). p-for-trend analyses suggested lower antibody titres with increasing fruit, vegetable, and salad intake, and higher titres with increasing intake of dairy or calcium-fortified alternatives and increasing age (table 3) .

In this large, prospective, population-based serological study, we explored determinants of SARS-CoV-2 seropositivity and antibody titres, evaluating more than 80 sociodemographic, clinical, and behavioural risk factors. We found that four factors-Asian/Asian British ethnicity, frontline occupation in health or social care, international travel, and high BMI-were strongly associated both with increased risk of SARS-CoV-2 seropositivity and with higher antibody titres in the subset of seropositive participants. Lower levels of educational attainment and light physical exercise and higher levels of alcohol consumption were found to associated with increased risk of SARS-CoV-2 seropositivity, as was use of vitamin D supplements. Low intake of dairy or calcium-fortified alternatives and high intake of fruit, vegetables, and salad were associated with lower antibody titres, as was reporting anxiety or depression. Importantly, most factors associated with antibody titres in seropositive participants retained significance after adjusting for disease severity.

Our results support previous studies that have found increased risk of SARS-CoV-2 seropositivity for healthcare workers, 3,4,12 people of Asian ethnicity, 3, 5, 12 and people with lower is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. ; https://doi.org/10.1101/2021.11.02.21265767 doi: medRxiv preprint educational attainment. 3, 4 Non-White race/ethnicity has previously been highlighted as a determinant of both SARS-CoV-2 seropositivity 22-24 and antibody titres, 25 but questions remained over residual confounding. 22 Despite including a wide range of potential confounders, point estimates for all non-White participants remained higher in both our seropositivity and titre analyses, and significantly so for Asian/Asian British participants, emphasising the need to investigate the underlying biological or social factors driving this disparity. While we did not confirm increased seropositivity for Black participants, we lacked statistical power, as they represented only 0.4% of the cohort.

We identified two modifiable lifestyle factors associated with SARS-CoV-2 seropositivity: alcohol consumption and light physical exercise. High levels of alcohol intake are known to negatively affect immune response through several mechanisms, 26 which supports our finding of increased risk among participants consuming more than 15 units of alcohol a week. By contrast, we observed reduced risk among participants doing more than 10 hours of light physical exercise per week. It has been speculated that there is a J-shaped relationship between exercise load and susceptibility to infection, whereby moderate exercise can improve immune response, but prolonged, high-intensity exercise can increase susceptibility to infection. 27 This curve might explain why we did not see similar benefits for vigorous physical activity.

Our finding that use of vitamin D supplements was associated with increased risk of seropositivity contrasts with a previous study, which found lower risk in a univariable model and no association after adjusting for confounders; 23 randomised controlled trials are needed to resolve questions around potential effects of vitamin D supplements on susceptibility to SARS-CoV-2. We found no associations for frontline workers not based in health or social care, at odds with previous findings. 11, 12 We also did not observe associations between seropositivity and age or sex, unlike other studies. 5, 23, 24, 28, 29 This may reflect the fact that we adjusted for more potential confounders than most of these studies, and included behaviours that reflect social mixing and influence exposure to infected individuals.

After adjustment for disease severity, we uncovered six factors associated with higher titres (Asian/Asian British ethnicity, working as a frontline worker in the health or care setting, international travel, taking multivitamin supplements, increased consumption of dairy products or calcium-fortified alternatives, and use of beta blockers) and four associated with lower titres (male sex; IMD quartile; high levels of fruit, vegetable, or salad consumption; and reporting feeling anxious or depressed at baseline). Different mechanisms may explain these associations. High intensity and frequency of exposure could be a cause of elevated antibody titres in participants who travelled abroad and in frontline health and social care workers, 30 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. supported by previous findings of higher titres in healthcare workers. 14 Alternatively, greater immune reactivity could be a cause of higher titres, as seen in female participants, who generally have stronger innate and adaptive immune responses than males. 31 Diet and nutrition are known to affect immune responses 32 and thus might explain the higher titres observed with use of multivitamin supplements and higher levels of dairy intake (potentially reflecting higher calcium intakes). 33 However, little evidence is available for the effect of vitamin supplementation in suboptimal rather than micronutrient-deficient diets, 32 and after adjustment, we found no associations between intake of any individual vitamin supplements and antibody titres. The negative association with fruit, vegetable, and salad consumption was observed for the highest level of intake only (≥6 portions a day); however, despite 40% of vegan or vegetarian participants being included in that category, neither diet type was found to be associated with antibody titres, suggesting it is not the result of a restricted diet. We observed a significant positive dose-response relationship with age, supporting findings from other studies. 13, 34, 35 This association was not attenuated by adjustment for disease severity, suggesting that other mechanisms relating to the effects of age on host responses might be responsible. 36 This study has several strengths. Use of serology to measure SARS-CoV-2 infection reduces collider bias, as serology testing was offered to all participants enrolled in COVIDENCE UK, in contrast to results from external routine testing that had limited availability, particularly at the start of the pandemic. Serology testing has also allowed us to better quantify the risk of SARS-CoV-2 infection by capturing previous infections that were asymptomatic or unconfirmed. A further strength is the use of an assay with high sensitivity and specificity that targets three different types of antibody, 37 increasing the probability of identifying a past infection. Additionally, we used dried blood spots for our sampling, which have been found to reduce processing failures compared with microtubes, 38 which are currently used by large seroprevalence surveys. 39 The prospective nature of our study reduces the potential for reverse causation explaining our findings, and the granularity of our questionnaire allowed us to explore potential determinants and confounders that other studies have not investigated.

Our study also has some limitations. First, COVIDENCE UK is a self-selected cohort, and thus several groups-such as people younger than 30 years, people of lower socioeconomic status, and non-White ethnic groups-are under-represented. This particularly affected our power to investigate outcomes for Black participants, who have been found to be at higher risk of SARS-CoV-2 infection 4,5,12 and adverse outcomes 22 than White people. However, insufficient representativeness in a cohort does not preclude identification of causal associations, and self-selection may result in better response to follow-up. 40 Second, as we included asymptomatic infections in our titre analysis, we were not able to adjust for timing of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. ; https://doi.org/10.1101/2021.11.02.21265767 doi: medRxiv preprint infection onset, preventing us from capturing the effects of temporal changes in antibody responses. As 40% of our seropositive participants did not experience symptoms suggestive of COVID-19 or provide a symptom onset date, excluding them would have greatly reduced the power and generalisability of our analysis. Third, as with any observational study, we cannot exclude the possibility that some of the associations we report might be explained by residual or unmeasured confounding. For example, the finding that passive smoking but not active smoking reduces the risk of seropositivity compared with never-smokers should be treated with caution, unless a plausible protective mechanism can be found. However, we have minimised the risk of confounding by adjusting for a comprehensive list of putative risk factors, and hope that future studies can investigate the robustness of the associations found.

In conclusion, this prospective serological study shows that people of Asian/Asian British ethnicity, frontline workers in health or social care, people with high BMI, and those who had travelled abroad were at higher risk of SARS-CoV-2 seropositivity, after robust adjustment for confounders, and shows that these factors are also determinants of antibody titres, regardless of disease severity. We additionally show that alcohol consumption and physical exercise, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. 

De-identified participant data will be made available upon reasonable request to the corresponding author.

This study was supported by a grant from Barts Charity to ARM and CJG (MGU0466). The is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. ; https://doi.org/10.1101/2021.11.02.21265767 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. ; https://doi.org/10.1101/2021.11.02.21265767 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. ; https://doi.org/10.1101/2021.11.02.21265767 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. ; https://doi.org/10.1101/2021.11.02.21265767 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Data are n (%), n/N (%), or GMR (95% CI). Both fully adjusted analyses included 1697 participants with data available for all factors. BMI=body-mass index. BTEC=Business and Technology Education Council. COPD=chronic obstructive pulmonary disease. GMR=geometric mean ratio. IMD=index of multiple deprivation. *Adjusted for age, sex, and duration of follow-up. †Adjusted for duration of follow-up and all factors shown except symptom severity. ‡Adjusted for duration of follow-up and all factors shown. §The 217 participants with unknown or missing travel status were included in the analysis as a separate category to ensure greater power. ¶Coronary artery disease or heart failure. || COVID-19 severity was classified as 'asymptomatic' (nonhospitalised participants who either did not report any symptoms of acute respiratory infection, or whose symptoms were classified as having <50% probability of being due to COVID-19); 'symptomatic, not hospitalised' (non-hospitalised participants reporting symptoms of acute respiratory infection that were classified as having ≥50% probability of being due to COVID-19); and 'hospitalised' (participants hospitalised for treatment of COVID-19)

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. ; https://doi.org/10.1101/2021.11.02.21265767 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. ; https://doi.org/10.1101/2021.11.02.21265767 doi: medRxiv preprint hospitalised participants who either did not report any symptoms of acute respiratory infection, or whose symptoms were classified as having <50% probability of being due to COVID-19); 'symptomatic, not hospitalised' (non-hospitalised participants reporting symptoms of acute respiratory infection that were classified as having ≥50% probability of being due to COVID-19); and 'hospitalised' (participants hospitalised for treatment of COVID-19). IgGAM=IgG, IgA, and IgM. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 3, 2021. ; https://doi.org/10.1101/2021.11.02.21265767 doi: medRxiv preprint

Coronavirus resource center

Tracking covid-19 excess deaths across countries. The Economist

Characteristics and Behaviors Associated with Prevalent SARS-CoV-2 Infection

Risk factors for positive and negative COVID-19 tests: a cautious and in-depth analysis of UK biobank data

A model of disparities: risk factors associated with COVID-19 infection

Collider bias undermines our understanding of COVID-19 disease risk and severity

COVID-19 testing policies

Insights into SARS-CoV-2 Persistence and Its Relevance

Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection-A retrospective observational case-controlled study

Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study

SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic

The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers

Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers: a cross-sectional study

Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients

Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK)

Site-specific glycan analysis of the SARS-CoV-2 spike

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

No adjustments are needed for multiple comparisons

Real-time tracking of self-reported symptoms to predict potential COVID-19

Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain

Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform

Anticholinergics No 1685 (95.0%)

Metformin No 1720 (97.0%)

Statins No 1487 (83.8%)